ACE Report Cover
Dextrose Prolotherapy Improved Pain & Function in LE Patients Compared to HA at 12 Weeks
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
SHOULDER & ELBOW
Dextrose Prolotherapy Improved Pain & Function in LE Patients Compared to HA at 12 Weeks

Injection Therapy in Patients with Lateral Epicondylalgia: Hyaluronic Acid or Dextrose Prolotherapy? A Single-Blind, Randomized Clinical Trial.

J Altern Complement Med . 2020 Dec;26(12):1169-1175
Contributing Authors

H Apaydin Z Bazancir Z Altay

Thirty-two patients with chronic lateral epicondylalgia (LE) were randomized to receive an injection with single dose pf high-molecular-weight hyaluronic acid (HA) or 3 doses of dextrose prolotherapy (DPT). The primary outcomes of interest included pain at rest, during movement, and at night on a Visual Analogue Scale (VAS), and physical function evaluated with the Quick-Disabilities of the Arm, Shoulder, and Hand (Q-DASH) score. Secondary outcomes of interest included grip strength. All outcomes were measured at 6 and 12 weeks follow up. Results revealed that whilst both groups reported improvements in pain, function and grip strength, the improvement from baseline at 12 weeks for VAS pain at rest (p=0.04), during movement (p=0.04), and at night (p=0.03) and Q-DASH scores were statistically significantly greater in the DPT group compared to the HA group.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Dextrose Prolotherapy Improved Pain & Function in LE Patients Compared to HA at 12 Weeks. ACE Report. 2021;10(1):22. Available from: https://myorthoevidence.com/AceReport/Show/dextrose-prolotherapy-improved-pain-function-in-le-patients-compared-to-ha-at-12-weeks

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report